Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date

References

• OlsenEA. Female pattern hair loss. J Am Acad Dermatol. 2001;45(3 Suppl):S70–80. doi:10.1067/mjd.2001.11742611511856
   PubMed Web of Science ®Google Scholar
• RojhirunsakoolS, SuchonwanitP. Parietal scalp is another affected area in female pattern hair loss: an analysis of hair density and hair diameter. Clin Cosmet Investig Dermatol. 2018;11:7–12. doi:10.2147/CCID.S153768
   PubMed Web of Science ®Google Scholar
• PriceVH, RobertsJL, HordinskyM, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43(5):768–776. doi:10.1067/mjd.2000.10795311050579
   PubMed Web of Science ®Google Scholar
• OlsenEA, MessengerAG, ShapiroJ, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005;52(2):301–311. doi:10.1016/j.jaad.2004.04.00815692478
   PubMed Web of Science ®Google Scholar
• StoutSM, StumpfJL. Finasteride treatment of hair loss in women. Ann Pharmacother. 2010;44(6):1090–1097. doi:10.1345/aph.1M59120442354
   PubMed Web of Science ®Google Scholar
• RogersNE, AvramMR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008;59(4):547–566; quiz 567-548. doi:10.1016/j.jaad.2008.07.001
   Web of Science ®Google Scholar
• SuchonwanitP, ThammaruchaS, LeerunyakulK. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777–2786. doi:10.2147/DDDT.S214907
   PubMed Web of Science ®Google Scholar
• SuchonwanitP, ChalermrojN, KhunkhetS. Low-level laser therapy for the treatment of androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device-controlled trial. Lasers Med Sci. 2019;34(6):1107–1114. doi:10.1007/s10103-018-02699-930569416
   PubMed Web of Science ®Google Scholar
• LeeGY, LeeSJ, KimWS. The effect of a 1550 nm fractional erbium-glass laser in female pattern hair loss. J Eur Acad Dermatol Venereol. 2011;25(12):1450–1454. doi:10.1111/j.1468-3083.2011.04183.x21812832
   PubMed Web of Science ®Google Scholar
• SuchonwanitP, RojhirunsakoolS, KhunkhetS. A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. Lasers Med Sci. 2019;34(9):1857–1864. doi:10.1007/s10103-019-02783-830982177
   PubMed Web of Science ®Google Scholar
• GentileP, ColeJP, ColeMA, et al. Evaluation of not-activated and activated PRP in hair loss treatment: role of growth factor and cytokine concentrations obtained by different collection systems. Int J Mol Sci. 2017;18(2):E408. doi:10.3390/ijms1802040828216604
   PubMed Web of Science ®Google Scholar
• GentileP. Autologous cellular method using micrografts of human adipose tissue derived follicle stem cells in androgenic alopecia. Int J Mol Sci. 2019;20(14):E3446. doi:10.3390/ijms2014344631337037
   PubMed Web of Science ®Google Scholar
• HuAC, ChapmanLW, MesinkovskaNA. The efficacy and use of finasteride in women: a systematic review. Int J Dermatol. 2019;58(7):759–776. doi:10.1111/ijd.2019.58.issue-730604525
   PubMed Web of Science ®Google Scholar
• van ZuurenEJ, FedorowiczZ, SchoonesJ. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2016;5(5):Cd007628.
   Google Scholar
• DallobAL, SadickNS, UngerW, et al. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab. 1994;79(3):703–706. doi:10.1210/jcem.79.3.80773498077349
   PubMed Web of Science ®Google Scholar
• OhtawaM, MorikawaH, ShimazakiJ. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers. Eur J Drug Metab Pharmacokinet. 1991;16(1):15–21. doi:10.1007/BF031898691657611
   PubMed Web of Science ®Google Scholar
• CarlinJR, HoglundP, ErikssonLO, et al. Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. Drug Metab Dispos. 1992;20(2):148–155.1352203
   PubMed Web of Science ®Google Scholar
• MatzkinH, ChenJ, LewyshonO, AyalonD, BrafZ. Effects of long term treatment with finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating LH, FSH, prolactin and estradiol. Horm Metab Res. 1992;24(10):498–499. doi:10.1055/s-2007-10033731281461
   PubMed Web of Science ®Google Scholar
• Hulin-CurtisSL, PetitD, FiggWD, HsingAW, ReichardtJK. Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. Future Oncol. 2010;6(12):1897–1913. doi:10.2217/fon.10.14921142863
   PubMed Web of Science ®Google Scholar
• GormleyGJ, StonerE, RittmasterRS, et al. Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab. 1990;70(4):1136–1141. doi:10.1210/jcem-70-4-11362156887
   PubMed Web of Science ®Google Scholar
• GregoireS, WinchellGA, ConstanzerM, et al. Multiple dose pharmacokinetics of finasteride, a 5a-reductase inhibitor in men 45–60 and 370 years old [abstract]. Pharm Res. 1990;7:S–53.
   Google Scholar
• PrahaladaS, TarantalAF, HarrisGS, et al. Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta). Teratology. 1997;55(2):119–131. doi:10.1002/(ISSN)1096-99269143092
   PubMedGoogle Scholar
• ShenoyNK, PrabhakarSM. Finasteride and male breast cancer: does the MHRA report show a link? J Cutan Aesthet Surg. 2010;3(2):102–105. doi:10.4103/0974-2077.6902221031070
   PubMedGoogle Scholar
• Moreno-ArronesOM, BecerraA, Vano-GalvanS. Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients. Clin Exp Dermatol. 2017;42(7):743–748. doi:10.1111/ced.2017.42.issue-728691187
   PubMed Web of Science ®Google Scholar
• ThaiKE, SinclairRD. Finasteride for female androgenetic alopecia. Br J Dermatol. 2002;147(4):812–813. doi:10.1046/j.1365-2133.2002.49084.x12366441
   PubMed Web of Science ®Google Scholar
• ValsecchiR, LeghissaP, RivaM. Female androgenetic alopecia treated by finasteride: a case forward. Acta Derm Venereol. 2004;84(6):488–489.15844649
   PubMed Web of Science ®Google Scholar
• HongJB, ChiuHC, ChanJY, ChenRJ, LinSJ. A woman with iatrogenic androgenetic alopecia responding to finasteride. Br J Dermatol. 2007;156(4):754–755. doi:10.1111/j.1365-2133.2006.07719.x17263815
   PubMed Web of Science ®Google Scholar
• BoychenkoO, BernsteinRM, SchweigerES. Finasteride in the treatment of female pattern (androgenic) alopecia: a case report and review of the literature. Cutis. 2012;90(2):73–76.22988650
   PubMed Web of Science ®Google Scholar
• ShumKW, CullenDR, MessengerAG. Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol. 2002;47(5):733–739. doi:10.1067/mjd.2002.12460812399766
   PubMed Web of Science ®Google Scholar
• IorizzoM, VincenziC, VoudourisS, PiracciniBM, TostiA. Finasteride treatment of female pattern hair loss. Arch Dermatol. 2006;142(3):298–302. doi:10.1001/archderm.142.3.29816549704
   PubMed Web of Science ®Google Scholar
• WhitingDA, WaldstreicherJ, SanchezM, KaufmanKD. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc. 1999;4(3):282–284. doi:10.1038/sj.jidsp.5640230
   PubMedGoogle Scholar
• KimWJ, SongM, KoHC, KimBS, KimMB. Efficacy of finasteride 1.25 mg on female pattern hair loss; pilot study. Ann Dermatol. 2012;24(3):370–372. doi:10.5021/ad.2012.24.3.37022879729
   PubMed Web of Science ®Google Scholar
• BoersmaIH, OranjeAP, GrimaltR, IorizzoM, PiracciniBM, VerdonschotEH. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2014;80(6):521–525. doi:10.4103/0378-6323.14416225382509
   PubMed Web of Science ®Google Scholar
• TruebRM. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology. 2004;209(3):202–207. doi:10.1159/00007989015459533
   PubMed Web of Science ®Google Scholar
• KohlerC, TschumiK, BodmerC, SchneiterM, BirkhaeuserM. Effect of finasteride 5 mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. Gynecol Endocrinol. 2007;23(3):142–145. doi:10.1080/0951359070121446317454167
   PubMed Web of Science ®Google Scholar
• CarminaE, LoboRA. Treatment of hyperandrogenic alopecia in women. Fertil Steril. 2003;79(1):91–95. doi:10.1016/S0015-0282(02)04551-X12524069
   PubMed Web of Science ®Google Scholar
• YeonJH, JungJY, ChoiJW, et al. 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol. 2011;25(2):211–214. doi:10.1111/jdv.2010.25.issue-220569283
   PubMed Web of Science ®Google Scholar
• Oliveira-SoaresR, e SilvaJM, CorreiaMP, AndreMC. Finasteride 5 mg/day treatment of patterned hair loss in normo-androgenetic postmenopausal women. Int J Trichol. 2013;5(1):22–25. doi:10.4103/0974-7753.114709
   PubMedGoogle Scholar
• ZhaoJ, HaradaN, OkajimaK. Dihydrotestosterone inhibits hair growth in mice by inhibiting insulin-like growth factor-I production in dermal papillae. Growth Horm IGF Res. 2011;21(5):260–267. doi:10.1016/j.ghir.2011.07.00321839661
   PubMed Web of Science ®Google Scholar
• TangL, BernardoO, BolducC, LuiH, MadaniS, ShapiroJ. The expression of insulin-like growth factor 1 in follicular dermal papillae correlates with therapeutic efficacy of finasteride in androgenetic alopecia. J Am Acad Dermatol. 2003;49(2):229–233. doi:10.1067/S0190-9622(03)00777-112894070
   PubMed Web of Science ®Google Scholar
• Hugh RushtonD, NorrisMJ, Van NesteD. Hair regrowth in male and female pattern hair loss does not involve the conversion of vellus hair to terminal hair. Exp Dermatol. 2016;25:482–484. doi:10.1111/exd.1294526782302
   PubMed Web of Science ®Google Scholar
• SuchonwanitP, SrisuwanwattanaP, ChalermrojN, KhunkhetS. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018;32(12):2257–2263. doi:10.1111/jdv.2018.32.issue-1229972712
   PubMed Web of Science ®Google Scholar
• MazzarellaGF, LoconsoleGF, CammisaGA, MastrolonardoGM, VenaGA. Topical finasteride in the treatment of androgenetic alopecia: preliminary evaluations after a 16-month therapy course. J Dermatol Treat. 1997;8:189–192. doi:10.3109/09546639709160517
   Web of Science ®Google Scholar
• SuchonwanitP, IamsumangW, RojhirunsakoolS. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. Am J Clin Dermatol. 2019;20(1):147–153. doi:10.1007/s40257-018-0387-030206824
   PubMed Web of Science ®Google Scholar
• SealeLR, EgliniAN, McMichaelAJ. Side effects related to 5 alpha-reductase inhibitor treatment of hair loss in women: a review. J Drugs Dermatol. 2016;15(4):414–419.27050696
   PubMed Web of Science ®Google Scholar
• McClellanKJ, MarkhamA. Finasteride: a review of its use in male pattern hair loss. Drugs. 1999;57(1):111–126. doi:10.2165/00003495-199957010-000149951956
   PubMed Web of Science ®Google Scholar
• GuptaAK, SharmaN, ShuklaP. Atypical post-finasteride syndrome: a pharmacological riddle. Indian J Pharmacol. 2016;48(3):316–317. doi:10.4103/0253-7613.18289827298504
   PubMed Web of Science ®Google Scholar
• ClarkRV, HermannDJ, CunninghamGR, WilsonTH, MorrillBB, HobbsS. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179–2184. doi:10.1210/jc.2003-03033015126539
   PubMed Web of Science ®Google Scholar
• OlsenEA, HordinskyM, WhitingD, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014–1023. doi:10.1016/j.jaad.2006.05.00717110217
   PubMed Web of Science ®Google Scholar
• GuptaAK, CharretteA. The efficacy and safety of 5alpha-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. J Dermatolog Treat. 2014;25(2):156–161. doi:10.3109/09546634.2013.81301123768246
   PubMed Web of Science ®Google Scholar
• OlszewskaM, RudnickaL. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol. 2005;4(5):637–640.16167423
   PubMedGoogle Scholar